BC
IRWD icon

Bridgefront Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bridgefront Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,327
Closed -$142K – 577
2024
Q1 		$142K Buy
+16,327
New +$198K 0.11% 339
2022
Q4 		– Sell
-15,396
Closed -$160K – 438
2022
Q3 		$160K Buy
+15,396
New +$175K 0.16% 250
2021
Q1 		– Sell
-18,047
Closed -$206K – 796
2020
Q4 		$206K Buy
+18,047
New +$197K 0.07% 506

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Bridgefront Capital's IRWD Position: Q2 2024 in Review

Bridgefront Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2024, closing a stake of 16,327 shares — an estimated $142K sold.

Bridgefront Capital first reported a position in IRWD in Q4 2020 and held it in 3 quarters. The position peaked at $206K in Q4 2020. 226 funds tracked by Wall St. Rank hold IRWD as of Q2 2024.

  • Bridgefront Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bridgefront Capital sold 16,327 Ironwood Pharmaceuticals shares in Q2 2024, an estimated $142K.
  • Bridgefront Capital first reported a position in Ironwood Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Bridgefront Capital's Ironwood Pharmaceuticals position peaked at $206K in Q4 2020.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2024.

Based on Bridgefront Capital's 13F filing for Q2 2024, filed 14 Aug 2024.